Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sleep disorders

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    544 result(s) found for: Sleep disorders. Displaying page 1 of 28.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-005103-33 Sponsor Protocol Number: WEL-SOM01-2006/01 Start Date*: 2007-01-26
    Sponsor Name:Laboratoires WELEDA
    Full Title: Study of sleep characteristics and parameters in patients suffering from minors sleep disorders treated by the homeopathic medicinal product Somnidoron®, oral drops, solution.
    Medical condition: Minors sleep disorders
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040984 Sleep disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005719-89 Sponsor Protocol Number: 12440 / R-0631M / Melody Start Date*: 2007-01-04
    Sponsor Name:Meander Medical Center
    Full Title: Double blind placebo controlled study on the efficacy of melatonin on sleep parameters and quality of life in hemodialysis patients
    Medical condition: Sleep problems in hemodialysis patients
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040991 Sleep disorders and disturbances HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-004640-78 Sponsor Protocol Number: ITI-007-004 Start Date*: 2007-11-13
    Sponsor Name:Intra-Cellular Therapies, Inc
    Full Title: A randomized, double-blind, placebo-controlled, 4-way crossover study of ITI-007 in subjects with sleep maintenance insomnia
    Medical condition: Sleep maintenance disorders
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040984 Sleep disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002875-15 Sponsor Protocol Number: TAK-375_107 Start Date*: 2007-12-11
    Sponsor Name:Takeda
    Full Title: A Single-Center, Randomized, Double-Blind, Double-Dummy Placebo Controlled, Cross-Over Study to Investigate the Next Morning Effects of Ramelteon (8mg), Zopiclone (7.5mg) and Placebo on Actual Driv...
    Medical condition: insomnia characterised by difficulty with sleep onset
    Disease: Version SOC Term Classification Code Term Level
    10.0 10040984 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-004644-35 Sponsor Protocol Number: PKD10491 Start Date*: 2015-03-17
    Sponsor Name:Sanofi-aventis
    Full Title: Single dose, open label safety, tolerability, pharmacokinetic and pharmacodynamic evaluation of three different eplivanserin doses in children aged 6-17 years with insomnia of various origins
    Medical condition: Sleep Initiation and Maintenance Disorders
    Disease: Version SOC Term Classification Code Term Level
    17.1 10037175 - Psychiatric disorders 10040984 Sleep disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-002213-21 Sponsor Protocol Number: VP-VEC-162-2102 Start Date*: 2016-08-15
    Sponsor Name:Vanda Pharmaceuticals Inc
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL PROOF OF CONCEPT STUDY TO EVALUATE THE EFFECTS OF MULTIPLE ORAL DOSES OF TASIMELTEON AND MATCHING PLACEBO IN TRAVELERS WITH JET...
    Medical condition: Jet Lag Disorder (JLD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10040984 Sleep disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-005475-40 Sponsor Protocol Number: VP-VEC-162-3502 Start Date*: 2022-06-08
    Sponsor Name:Vanda Pharmaceuticals Inc.
    Full Title: A multicenter, double-blind, randomized study to evaluate the effects of tasimelteon vs. placebo in participants with Delayed Sleep-Wake Phase Disorder (DSWPD)
    Medical condition: Delayed Sleep-Wake Phase Disorder (DSWPD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10041013 Sleep-wake schedule disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003119-39 Sponsor Protocol Number: 38RC15.175 Start Date*: 2015-10-29
    Sponsor Name:Centre Hospitalier Universitaire de Grenoble
    Full Title: effects of a short therpay of zolpidem with support servo-ventilation versus placebo in patients with central sleep apnea with chronic heart failure
    Medical condition: chronic heart failure and central sleep apnea
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10040979 Sleep apnoea syndrome PT
    18.1 100000004849 10019276 Heart disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003198-14 Sponsor Protocol Number: VP-VEC-162-3106 Start Date*: 2015-12-21
    Sponsor Name:Vanda Pharmaceuticals Inc
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel study to investigate the efficacy and safety of multiple oral doses of tasimelteon and matching placebo in travelers with Jet L...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.1 10037175 - Psychiatric disorders 10040984 Sleep disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004025-28 Sponsor Protocol Number: HTA 05-14-02 Start Date*: 2007-06-26
    Sponsor Name:Royal Liverpool Children’s NHS Trust
    Full Title: MENDS: The use of MElatonin in children with Neuro-developmental Disorders and impaired Sleep; a randomised, double-blind, placebo-controlled, parallel study
    Medical condition: children with neuro-developmental disorders and impaired sleep
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064062 Neurodevelopmental disorder PT
    9.1 10040984 Sleep disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004520-35 Sponsor Protocol Number: VP-VEC-162-3204 Start Date*: 2012-12-06
    Sponsor Name:Vanda Pharmaceuticals Inc.
    Full Title: AN EXTENSION OPEN-LABEL SAFETY STUDY OF A 24-MONTH 20MG DOSE REGIMEN OF TASIMELTEON FOR THE TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER (N24HSWD) IN BLIND INDIVIDUALS WITH NO LIGHT PERCEPTION WHO ...
    Medical condition: Blind males or females with no conscious light perception and the complaint of a sleep-wake disorder associated with Non-24 Hour Sleep- Wake Disorder
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029205 - Nervous system disorders 10009191 Circadian rhythm sleep disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-002174-58 Sponsor Protocol Number: ACT6796 Start Date*: 2007-11-30
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A double-blind, randomized, placebo-controlled, study of the safety and activity of four escalating single doses of AVE0657 in patients suffering from Obstructive Sleep Apnea Hypopnea Syndrome
    Medical condition: Patients suffering from Obstructiv-Sleep Apnea Hypopnea Syndrome (OSAHS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055577 Obstructive sleep apnea syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000281-35 Sponsor Protocol Number: VP-VEC-162-3201 Start Date*: 2011-06-09
    Sponsor Name:Vanda Pharmaceuticals Inc.
    Full Title: A Multicenter, Randomized, Double-Mask, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of 20 mg Tasimelteon versus Placebo in Totally Blind Subjects with N24HSWD followed...
    Medical condition: Blind males or females with no conscious light perception and the complaint of a sleep-wake disorder associated with Non-24 Hour Sleep-Wake Disorder.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10009191 Circadian rhythm sleep disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003394-15 Sponsor Protocol Number: VP-VEC-162-4201 Start Date*: 2016-06-28
    Sponsor Name:Vanda Pharmaceuitcals Inc.
    Full Title: OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SAFETY OF TASIMELTEON IN TOTALLY BLIND CHILDREN AND ADOLESCENTS WITH NON-24-HOUR SLEEP- WAKE DISORDER
    Medical condition: This study will be an open-label, single dose, non-controlled trial to evaluate the pharmacokinetics and safety of tasimelteon in children who are 3 years to less than 18 years of age, totally blin...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10040984 Sleep disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002926-26 Sponsor Protocol Number: STM-042/K Start Date*: 2021-11-15
    Sponsor Name:Desitin Arzneimittel GmbH
    Full Title: Efficacy, Safety and Tolerability of 3 doses of Sulthiame in Patients with Obstructive Sleep Apnea. A Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study
    Medical condition: Obstructive sleep apnea
    Disease: Version SOC Term Classification Code Term Level
    25.0 100000004855 10055577 Obstructive sleep apnea syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Ongoing) CZ (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003037-41 Sponsor Protocol Number: MUG-EROS-2012 Start Date*: 2012-09-21
    Sponsor Name:Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Klinische Abteilung für Lungenkrankheiten
    Full Title: Effects of Roflumilast on pulmonary vascular resistance in patients with COPD and sleep apnea (Overlap Syndrome) with and without non-invasive ventilation. A Pilot Study.
    Medical condition: This study is about pulmonary hypertension due to lung diseases. The lung disease in this study will be the overlap syndrome which is defined as chronic obstructive pulmonary disease concomitant wi...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10040976 Sleep apnea syndrome LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005792-16 Sponsor Protocol Number: Rocuronium_HVR_OSAS Start Date*: 2012-02-10
    Sponsor Name:Karolinska University Hospital
    Full Title: Effect of reduced cholinergic transmission by rocuronium on the hypoxic ventilatory response in patients with obstructive sleep apnea - before and after three months of continous positive airway pr...
    Medical condition: Obstuctive sleep apnea and acute hypoxic ventilatory response
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10055577 Obstructive sleep apnea syndrome LLT
    Population Age: Adults Gender: Male
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000037-36 Sponsor Protocol Number: KLF/K/010710 Start Date*: Information not available in EudraCT
    Sponsor Name:MCM Klosterfrau GmbH & Co. KG
    Full Title: Open label clinical trial to investigate the physiological effects on sleep of Nervenruh Baldrian Forte 600 in patients with primary insomnia
    Medical condition: Primary (psychophysiologic) insomnia
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10036701 Primary insomnia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-004552-41 Sponsor Protocol Number: I8F-MC-GPI2 Start Date*: 2022-09-14
    Sponsor Name:Eli Lilly and Company
    Full Title: A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants who have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Tria...
    Medical condition: Obstructive sleep apnea
    Disease: Version SOC Term Classification Code Term Level
    25.0 10038738 - Respiratory, thoracic and mediastinal disorders 10029983 Obstructive sleep apnoea syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-003766-27 Sponsor Protocol Number: 848015011 Start Date*: 2018-07-18
    Sponsor Name:VU University Medical Centre
    Full Title: The DREAMING study: Efficacy of low dose amitriptyline and mirtazapine for insomnia disorder: a double-blind, randomized, placebo-controlled trial in general practice
    Medical condition: Insonnia disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10078083 Insomnia disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 00:25:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA